Diagnostics / pathology

For Cancer That Reaches the CNS, a Payer Opens a Door

Fungal Disease Was Left Out of the AMR Fight

Dementia prevention has a cardiometabolic blind spot

Resistant hypertension may need a diagnostic revolution, not just another drug

AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved

Japan Approves MRD Testing. Price Will Decide Whether Patients Can Use It.

The Biomarker Test Cannot Wait Until Relapse

Gastric Cancer Gets a New Biomarker Access Signal

MRD Testing Moves From Prognosis Toward Treatment Action
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
